Karyopharm Expanded Access Program for Selinexor
Sponsor: Karyopharm Therapeutics Inc
ClinicalTrials ID:NCT07215832
This program allows patients to access the investigational drug selinexor before it is officially approved or available for sale in their country. It is intended for patients who have no other treatment options and do not qualify for ongoing clinical trials.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The Karyopharm Expanded Access Program (KEAP) is designed to provide the investigational drug selinexor to patients who might benefit from it but cannot join a clinical trial. This program is for patients who have tried all other available treatments without success. Selinexor is not yet approved for general use, so it is only available through this program. Patients can receive the drug through their doctors, who must get approval from the country's health authorities and follow all safety regulations.
Eligibility Criteria
Inclusion Criteria
-
Exclusion Criteria
-
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.